letrozole has been researched along with Carcinoma, Lobular in 25 studies
Carcinoma, Lobular: A type of BREAST CANCER where the abnormal malignant cells form in the lobules, or milk-producing glands, of the breast.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Participants were postmenopausal women with ER+, HER2 normal operable breast cancer assigned to 4 months of neoadjuvant letrozole." | 9.34 | Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. ( Ejlertsen, B; Jensen, MB; Knoop, AS; Laenkholm, AV; Skriver, SK, 2020) |
| "We report a case of Stage IV breast cancer in a 62-year-old woman who responded well to alternate-day S-1/letrozole combination therapy." | 7.81 | [Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis--A Case Report]. ( Fujita, Y; Muranishi, Y; Nakayama, I, 2015) |
| " We retrospectively investigated the activity of letrozole plus GnRH analogue (GnRH-a) administered concurrently with preoperative chemotherapy and as adjuvant treatment in premenopausal women with locally advanced ER positive breast cancer consecutively admitted at the European Institute of Oncology." | 7.77 | Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. ( Bagnardi, V; Colleoni, M; Goldhirsch, A; Iorfida, M; Luini, A; Rotmensz, N; Santoro, A; Scarano, E; Torrisi, R; Veronesi, P; Viale, G, 2011) |
| " Here we report a case of lobular breast cancer metastasizing to a leiomyoma in a patient using letrozole." | 7.77 | Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment. ( Aydinli, K; Basgul, AY; Calay, Z; Dünder, I; Güdücü, N; Işçi, H, 2011) |
| "Letrozole after 5 years of adjuvant tamoxifen results in a significant reduction in risk of recurrence from estrogen receptor (ER) positive breast cancer." | 7.74 | Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. ( Bryce, C; Chia, SK; Gelmon, KA; Kennecke, HF; Norris, B; Olivotto, IA; Speers, C, 2007) |
| "We report a breast cancer patient with leptomeningeal carcinomatosis (LM) who showed an excellent objective and subjective response to letrozole, with a progression-free survival of 16 months." | 7.72 | Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. ( Artac, M; Bozcuk, HS; Ozdogan, M; Sagtas, E; Samur, M; Savas, B; Yildiz, M, 2003) |
| " Further studies are needed to determine the feasibility of selecting an effective AI dosing schedule with better tolerability." | 6.82 | Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk. ( Boughey, JC; Chow, HH; Frank, D; Hsu, CH; Lang, JE; Ley, M; López, AM; Perloff, M; Pruthi, S; Taverna, JA, 2016) |
| "We enrolled patients with metastatic breast cancer to determine the safety and tumor response using Response Evaluation Criteria In Solid Tumors." | 6.82 | Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. ( Allred, JB; Goetz, MP; Ingle, JN; Moreno-Aspitia, A; Northfelt, DW; Perez, EA; Tan, WW, 2016) |
| "Participants were postmenopausal women with ER+, HER2 normal operable breast cancer assigned to 4 months of neoadjuvant letrozole." | 5.34 | Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial. ( Ejlertsen, B; Jensen, MB; Knoop, AS; Laenkholm, AV; Skriver, SK, 2020) |
| "Archival tumor tissue was available from 1323 Danish patients with estrogen receptor (ER) positive primary breast cancer, who participated in the Breast International Group (BIG) 1-98 trial, comparing treatment with tamoxifen and letrozole and both in a sequence." | 5.27 | Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. ( Ejlertsen, B; Giobbie-Hurder, A; Iversen, BR; Jensen, MB; Kirkegaard, T; Lykkesfeldt, AE; Rasmussen, BB; Reiter, BE, 2018) |
| "One hundred fifteen postmenopausal women with >2 cm, estrogen receptor (ER) or progesterone receptor (PgR)-positive breast cancer were enrolled in a trial of 16 to 24 weeks of letrozole 2." | 5.14 | Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. ( Bae, K; Budd, GT; Carey, LA; Commean, P; Ellis, MJ; Esserman, LJ; Fleming, GF; Giuntoli, T; Harris, LA; Leight, GS; Luo, J; Marcom, PK; Olson, JA, 2009) |
| "We report a case of Stage IV breast cancer in a 62-year-old woman who responded well to alternate-day S-1/letrozole combination therapy." | 3.81 | [Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis--A Case Report]. ( Fujita, Y; Muranishi, Y; Nakayama, I, 2015) |
| "Aromatase inhibitors (AIs) are more effective than tamoxifen as neoadjuvant endocrine therapy (NET) for hormone receptor (HR)-positive breast cancer." | 3.80 | Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer. ( Angelucci, D; Ausili Cefaro, G; Cianchetti, E; Cioffi, P; De Tursi, M; Di Nicola, M; Grassadonia, A; Grossi, S; Iacobelli, S; Iezzi, L; Marinelli, C; Natoli, C; Noccioli, P; Politi, R; Tavoletta, S; Tinari, N; Zilli, M, 2014) |
| " We retrospectively investigated the activity of letrozole plus GnRH analogue (GnRH-a) administered concurrently with preoperative chemotherapy and as adjuvant treatment in premenopausal women with locally advanced ER positive breast cancer consecutively admitted at the European Institute of Oncology." | 3.77 | Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer. ( Bagnardi, V; Colleoni, M; Goldhirsch, A; Iorfida, M; Luini, A; Rotmensz, N; Santoro, A; Scarano, E; Torrisi, R; Veronesi, P; Viale, G, 2011) |
| " Here we report a case of lobular breast cancer metastasizing to a leiomyoma in a patient using letrozole." | 3.77 | Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment. ( Aydinli, K; Basgul, AY; Calay, Z; Dünder, I; Güdücü, N; Işçi, H, 2011) |
| "Letrozole after 5 years of adjuvant tamoxifen results in a significant reduction in risk of recurrence from estrogen receptor (ER) positive breast cancer." | 3.74 | Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. ( Bryce, C; Chia, SK; Gelmon, KA; Kennecke, HF; Norris, B; Olivotto, IA; Speers, C, 2007) |
| "We report a breast cancer patient with leptomeningeal carcinomatosis (LM) who showed an excellent objective and subjective response to letrozole, with a progression-free survival of 16 months." | 3.72 | Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. ( Artac, M; Bozcuk, HS; Ozdogan, M; Sagtas, E; Samur, M; Savas, B; Yildiz, M, 2003) |
| " Further studies are needed to determine the feasibility of selecting an effective AI dosing schedule with better tolerability." | 2.82 | Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk. ( Boughey, JC; Chow, HH; Frank, D; Hsu, CH; Lang, JE; Ley, M; López, AM; Perloff, M; Pruthi, S; Taverna, JA, 2016) |
| "We enrolled patients with metastatic breast cancer to determine the safety and tumor response using Response Evaluation Criteria In Solid Tumors." | 2.82 | Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients. ( Allred, JB; Goetz, MP; Ingle, JN; Moreno-Aspitia, A; Northfelt, DW; Perez, EA; Tan, WW, 2016) |
| "Enophthalmos in the setting of breast cancer metastatic to the orbit results primarily from the disease pathogenesis, or secondary to treatment effects." | 1.48 | Orbital fat regeneration following hormonal treatment of metastatic breast carcinoma. ( Alameddine, RM; Kikkawa, DO; Ko, AC; Korn, BS; Lin, JH; Mimura, M; Parker, BA, 2018) |
| "Although approximately 60 % of breast cancers in premenopausal women are HR positive, the role of neoadjuvant ET in this population is not well defined." | 1.42 | Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience. ( Barbie, TU; Ma, C; Margenthaler, JA, 2015) |
| "The percentage of women≥75 years with breast cancer receiving PET in the south of the Netherlands decreased from 23% in the period 1988-1992 to 12% in 1997-2000, and increased to 29% in 2005-2008." | 1.38 | Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer. ( Hutschemaekers, S; Nieuwenhuijzen, GA; Roukema, JA; Tjan-Heijnen, VC; van der Sangen, MJ; Voogd, AC; Wink, CJ; Woensdregt, K, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (24.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Meynard, L | 1 |
| Grellety, T | 1 |
| Skriver, SK | 1 |
| Jensen, MB | 2 |
| Knoop, AS | 1 |
| Ejlertsen, B | 3 |
| Laenkholm, AV | 1 |
| Alameddine, RM | 1 |
| Ko, AC | 1 |
| Mimura, M | 1 |
| Parker, BA | 1 |
| Lin, JH | 1 |
| Korn, BS | 1 |
| Kikkawa, DO | 1 |
| Lykkesfeldt, AE | 1 |
| Iversen, BR | 1 |
| Giobbie-Hurder, A | 2 |
| Reiter, BE | 1 |
| Kirkegaard, T | 1 |
| Rasmussen, BB | 1 |
| Weiss, J | 1 |
| Afghahi, A | 1 |
| Shagisultanova, E | 1 |
| Diamond, JR | 1 |
| Guarneri, V | 1 |
| Dieci, MV | 1 |
| Bisagni, G | 1 |
| Frassoldati, A | 1 |
| Bianchi, GV | 1 |
| De Salvo, GL | 1 |
| Orvieto, E | 1 |
| Urso, L | 1 |
| Pascual, T | 1 |
| Paré, L | 1 |
| Galván, P | 1 |
| Ambroggi, M | 1 |
| Giorgi, CA | 1 |
| Moretti, G | 1 |
| Griguolo, G | 1 |
| Vicini, R | 1 |
| Prat, A | 1 |
| Conte, PF | 1 |
| Grassadonia, A | 1 |
| Di Nicola, M | 1 |
| Grossi, S | 1 |
| Noccioli, P | 1 |
| Tavoletta, S | 1 |
| Politi, R | 1 |
| Angelucci, D | 1 |
| Marinelli, C | 1 |
| Zilli, M | 1 |
| Ausili Cefaro, G | 1 |
| Tinari, N | 1 |
| De Tursi, M | 1 |
| Iezzi, L | 1 |
| Cioffi, P | 1 |
| Iacobelli, S | 1 |
| Natoli, C | 1 |
| Cianchetti, E | 1 |
| Arthur, LM | 1 |
| Turnbull, AK | 1 |
| Webber, VL | 1 |
| Larionov, AA | 1 |
| Renshaw, L | 2 |
| Kay, C | 1 |
| Thomas, JS | 1 |
| Dixon, JM | 2 |
| Sims, AH | 1 |
| Barbie, TU | 1 |
| Ma, C | 1 |
| Margenthaler, JA | 1 |
| Nakayama, I | 1 |
| Muranishi, Y | 1 |
| Fujita, Y | 1 |
| Metzger Filho, O | 1 |
| Mallon, E | 1 |
| Gusterson, B | 1 |
| Viale, G | 2 |
| Winer, EP | 1 |
| Thürlimann, B | 1 |
| Gelber, RD | 1 |
| Colleoni, M | 2 |
| Debled, M | 1 |
| Price, KN | 1 |
| Regan, MM | 1 |
| Coates, AS | 1 |
| Goldhirsch, A | 2 |
| López, AM | 1 |
| Pruthi, S | 1 |
| Boughey, JC | 1 |
| Perloff, M | 1 |
| Hsu, CH | 1 |
| Lang, JE | 1 |
| Ley, M | 1 |
| Frank, D | 1 |
| Taverna, JA | 1 |
| Chow, HH | 1 |
| Tan, WW | 1 |
| Allred, JB | 1 |
| Moreno-Aspitia, A | 1 |
| Northfelt, DW | 1 |
| Ingle, JN | 1 |
| Goetz, MP | 1 |
| Perez, EA | 1 |
| Sansone, P | 1 |
| Ceccarelli, C | 1 |
| Berishaj, M | 1 |
| Chang, Q | 1 |
| Rajasekhar, VK | 1 |
| Perna, F | 1 |
| Bowman, RL | 1 |
| Vidone, M | 1 |
| Daly, L | 1 |
| Nnoli, J | 1 |
| Santini, D | 1 |
| Taffurelli, M | 1 |
| Shih, NN | 1 |
| Feldman, M | 1 |
| Mao, JJ | 1 |
| Colameco, C | 1 |
| Chen, J | 1 |
| DeMichele, A | 1 |
| Fabbri, N | 1 |
| Healey, JH | 1 |
| Cricca, M | 1 |
| Gasparre, G | 1 |
| Lyden, D | 1 |
| Bonafé, M | 1 |
| Bromberg, J | 1 |
| Lince, SL | 1 |
| Douma, J | 1 |
| Wiersma-Van Tilburg, AJ | 1 |
| Kraayenbrink, AA | 1 |
| Olson, JA | 1 |
| Budd, GT | 1 |
| Carey, LA | 1 |
| Harris, LA | 1 |
| Esserman, LJ | 1 |
| Fleming, GF | 1 |
| Marcom, PK | 1 |
| Leight, GS | 1 |
| Giuntoli, T | 1 |
| Commean, P | 1 |
| Bae, K | 1 |
| Luo, J | 1 |
| Ellis, MJ | 1 |
| Torrisi, R | 1 |
| Bagnardi, V | 1 |
| Rotmensz, N | 1 |
| Scarano, E | 1 |
| Iorfida, M | 1 |
| Veronesi, P | 1 |
| Luini, A | 1 |
| Santoro, A | 1 |
| Dixon, J | 1 |
| Thomas, J | 1 |
| Wink, CJ | 1 |
| Woensdregt, K | 1 |
| Nieuwenhuijzen, GA | 1 |
| van der Sangen, MJ | 1 |
| Hutschemaekers, S | 1 |
| Roukema, JA | 1 |
| Tjan-Heijnen, VC | 1 |
| Voogd, AC | 1 |
| Işçi, H | 1 |
| Güdücü, N | 1 |
| Basgul, AY | 1 |
| Aydinli, K | 1 |
| Calay, Z | 1 |
| Dünder, I | 1 |
| Komeda, S | 1 |
| Furukawa, N | 1 |
| Kasai, T | 1 |
| Washida, A | 1 |
| Kobayashi, H | 1 |
| Ozdogan, M | 1 |
| Samur, M | 1 |
| Bozcuk, HS | 1 |
| Sagtas, E | 1 |
| Yildiz, M | 1 |
| Artac, M | 1 |
| Savas, B | 1 |
| Kennecke, HF | 1 |
| Olivotto, IA | 1 |
| Speers, C | 1 |
| Norris, B | 1 |
| Chia, SK | 1 |
| Bryce, C | 1 |
| Gelmon, KA | 1 |
| Goodwin, GM | 1 |
| Resnik, KS | 1 |
| DiLeonardo, M | 1 |
| Gibbons, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Trial of Endocrine Therapy Against Locoregional Therapy First. A DBCG Trial in Postmenopausal Patients With Operable Hormone Receptor Positive Tumors Larger Than 2 cm.[NCT00908531] | Phase 3 | 123 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Poor recruitement) | ||
| PERtuzumab-trastuzumab Plus lEetrozoLe In Endocrine Sensitive Breast Cancer: a Phase II neoAdjuvant Study[NCT02411344] | Phase 2 | 64 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors[NCT00004205] | Phase 3 | 8,028 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| Phase I Dose-Finding Trial of Letrozole in Postmenopausal Women at High Risk for Breast Cancer[NCT01077453] | Phase 1 | 112 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer[NCT01105312] | Phase 1/Phase 2 | 28 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical benefit rate will be estimated by the total number of patients with an objective status of CR, PR, or SD for duration of at least 6 months divided by the total number of evaluable patients. All evaluable patients will be used for this analysis. Exact binomial 95% confidence intervals for the true clinical benefit rate will be calculated. (NCT01105312)
Timeframe: from baseline up to 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II | 0 |
A confirmed response is defined to be a CR or PR (as determined by RECIST criteria) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Response will be evaluated using all cycles of treatment. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response. The number of confirmed responses will be reported here. (NCT01105312)
Timeframe: from baseline up to 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I: Dose Level One | 0 |
| Phase I: Dose Level Two | 2 |
Duration of response is defined for all evaluable patients who have achieved a confirmed response as the date at which the patient's objective status is first noted to be a CR or PR to the earliest date progression is documented. The distribution of duration of response will be estimated using the method of Kaplan-Meier. (NCT01105312)
Timeframe: from baseline up to 5 years post-registration
| Intervention | months (Median) |
|---|---|
| Phase II | NA |
MTD is defined as the dose level below the lowest dose that induces dose limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6> new patients). If dose-limiting toxicity (DLT) is not seen in any of the 3 patients, 3 new patients will be accrued and treated at the next higher dose level. If DLT are seen in 2 or 3 of 3 patients treated at a given dose level, then the next 3 patients will be treated at the next lower dose level, if only 3 patients were enrolled and treated at this lower dose level. The number of DLT's will be reported here. (NCT01105312)
Timeframe: Up to 2.5 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Phase I: Dose Level One | 1 |
| Phase I: Dose Level Two | 3 |
Progression-free survival (PFS) is defined as the time from registration to progression or death due to any cause. PFS at 6 months will be estimated. The distribution of PFS will be estimated using the method of Kaplan-Meier. (NCT01105312)
Timeframe: from baseline up to 6 months
| Intervention | months (Median) |
|---|---|
| Phase II | 2.1 |
"A confirmed response is defined to be a CR or PR (as determined by RECIST (version 1.1 criteria) noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Response will be evaluated using all cycles of treatment. All patients meeting the eligibility criteria who have signed a consent form and have begun treatment will be evaluable for response.~A CR is defined as:~All of the following must be true:~Disappearance of all non-nodal target lesions~Each target lymph node must have reduction in short axis to <1.0 cm~A PR is defined as:~At least a 30% decrease in the sum of the longest diameters of the non-nodal target lesions and the short axes of the target lymph nodes taking as reference the BSD (Section 11.41)" (NCT01105312)
Timeframe: from baseline up to 5 years post-registration
| Intervention | percentage of participants (Number) |
|---|---|
| Phase II | 0 |
Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier (NCT01105312)
Timeframe: from baseline up to 5 years post-registration
| Intervention | months (Median) |
|---|---|
| Phase II | 16.1 |
Time to treatment failure (TTF) is defined as the time from the date of registration to the date at which the patient is removed from treatment due to progression, unacceptable adverse events, or refusal. The distribution of TTF will be estimated using the method of Kaplan-Meier (NCT01105312)
Timeframe: from baseline up to 5 years post-registration
| Intervention | months (Median) |
|---|---|
| Phase II | 2 |
"Time-to-disease progression (TTP) is defined as the time from registration to documentation of disease progression. If a patient dies without a documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death. The distribution of TTP will be estimated using the method of Kaplan-Meier. Progression is defined as at least one of the following:~At least one new malignant lesion or a lymph node whose short axis has increased to >1.5 cm~At least a 20% increase in the sum of diameters of target lesions taking as reference the MSD. In addition, the sum must also demonstrate an absolute increase of at least 0.5 cm" (NCT01105312)
Timeframe: from baseline up to 6 months
| Intervention | months (Median) |
|---|---|
| Phase II | 2.1 |
8 trials available for letrozole and Carcinoma, Lobular
| Article | Year |
|---|---|
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Duct | 2020 |
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Duct | 2020 |
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Aurora Kinase A; Biomarkers; Breast Neoplasms | 2018 |
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Aurora Kinase A; Biomarkers; Breast Neoplasms | 2018 |
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2019 |
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2019 |
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase In | 2015 |
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase In | 2015 |
Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Double-Blind Method; | 2016 |
Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Lobular; Double-Blind Method; | 2016 |
Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2016 |
Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer Patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor | 2016 |
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinom | 2009 |
Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinom | 2009 |
Invasive lobular carcinoma: response to neoadjuvant letrozole therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Female; Humans | 2011 |
Invasive lobular carcinoma: response to neoadjuvant letrozole therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Female; Humans | 2011 |
17 other studies available for letrozole and Carcinoma, Lobular
| Article | Year |
|---|---|
CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity.
Topics: Alanine Transaminase; Aminopyridines; Aromatase Inhibitors; Aspartate Aminotransferases; Bone Neopla | 2020 |
CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity.
Topics: Alanine Transaminase; Aminopyridines; Aromatase Inhibitors; Aspartate Aminotransferases; Bone Neopla | 2020 |
Orbital fat regeneration following hormonal treatment of metastatic breast carcinoma.
Topics: Adipose Tissue; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobu | 2018 |
Orbital fat regeneration following hormonal treatment of metastatic breast carcinoma.
Topics: Adipose Tissue; Aged; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobu | 2018 |
Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles | 2018 |
Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzimidazoles | 2018 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2014 |
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neo | 2014 |
Molecular changes in lobular breast cancers in response to endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Cohort Studies; Female; Human | 2014 |
Molecular changes in lobular breast cancers in response to endocrine therapy.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Lobular; Cohort Studies; Female; Human | 2014 |
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
[Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Drug Combinati | 2015 |
[Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Lobular; Drug Combinati | 2015 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; | 2016 |
Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Topics: AC133 Antigen; Anastrozole; Androstadienes; Animals; Antigens, CD; Antineoplastic Agents, Hormonal; | 2016 |
Abnormal cervical smear: a sign of disseminated breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Female; Humans; Letrozole; Middle Aged; | 2008 |
Abnormal cervical smear: a sign of disseminated breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Female; Humans; Letrozole; Middle Aged; | 2008 |
Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2011 |
Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; | 2011 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2012 |
Hormone treatment without surgery for patients aged 75 years or older with operable breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neopla | 2012 |
Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Female; Humans; Leiomyoma; Letrozole; Mi | 2011 |
Lobular carcinoma of the breast metastasizing to leiomyoma in a patient under letrozole treatment.
Topics: Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Lobular; Female; Humans; Leiomyoma; Letrozole; Mi | 2011 |
Uterine metastasis of lobular breast cancer during adjuvant letrozole therapy.
Topics: Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobula | 2013 |
Uterine metastasis of lobular breast cancer during adjuvant letrozole therapy.
Topics: Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobula | 2013 |
Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuva | 2003 |
Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Lobular; Chemotherapy, Adjuva | 2003 |
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Br | 2007 |
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Br | 2007 |
Aromatase inhibitors and bipolar mood disorder: a case report.
Topics: Aggression; Anastrozole; Aromatase Inhibitors; Bipolar Disorder; Breast Neoplasms; Carcinoma, Lobula | 2006 |
Aromatase inhibitors and bipolar mood disorder: a case report.
Topics: Aggression; Anastrozole; Aromatase Inhibitors; Bipolar Disorder; Breast Neoplasms; Carcinoma, Lobula | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormon | 2006 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormon | 2006 |